MetaCap

CollPlant Biotechnologies (OPHI) vs Regentis Biomaterials (RGNT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CollPlant Biotechnologies is the larger company by market cap ($9.6 million vs $5.0 million), about 1.9 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OPHI-32.54%RGNT-42.51%
+2%-21%-45%
Nov 12, 20261 yearNov 20, 2026
OPHI-14.25%RGNT-41.58%
+2%-21%-44%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OPHI versus RGNT key metrics
MetricOPHIRGNT
Share price$3.13$0.7186
Market cap$9.63M$5.05M
1-day change-2.49%-14.42%
YTD return—-89.34%
EPS (TTM)$-9.33$-2.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.37M—
Revenue growth (YoY)+360.39%—
Net income (latest FY)$-11.49M$-13.65M
Gross margin64.78%—
Operating margin-484.31%—
Net margin-484.56%—
52-week high$22.50$15.50
52-week low$2.64$0.712
Distance from 52-week high-86.09%-95.36%
Analyst consensus—none
Avg. price target upside—+1291.59%
Average volume385.37K49.60K
Shares outstanding3.08M7.02M
SectorHealth CareHealth Care
IndustryIndustrial SpecialtiesIndustrial Specialties

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Regentis Biomaterials

RGNT stock →

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.

Health Care · Industrial Specialties

OPHI vs RGNT FAQ

Which is bigger, CollPlant Biotechnologies or Regentis Biomaterials?

CollPlant Biotechnologies (OPHI) is larger, with a market capitalization of $9.63M compared with $5.05M for Regentis Biomaterials (RGNT).

Are CollPlant Biotechnologies and Regentis Biomaterials in the same industry?

Yes. Both are classified in the Industrial Specialties industry within the Health Care sector.

More comparisons